None
RO
US FDA Approves First Daily Oral GLP‑1 Treatment for Weight Management, Showing Comparable Results to Injectable Therapy
['Digit Is A Versatile Content Creator With Expertise In Health', 'Technology', 'Movies', 'News. With Over Years Of Experience', 'He Delivers Well-Researched', 'Engaging', 'Insightful Articles That Inform', 'Entertain Readers. Passionate About Keeping His Audience Updated With Accurate', 'Relevant Information', 'Digit Combines Factual Reporting With Actionable Insights. Follow His Latest Updates']
Digitpatrox
With the approval of our once-daily oral GLP-1 treatment, patients will have a convenient pill option that can help them achieve weight loss comparable to injectable therapy,” said Mike Doustdar, president and CEO of Novo Nordisk.
The findings suggest the oral option can deliver weight loss comparable to the once-weekly injectable version already available.
At present, a once-weekly injectable GLP-1 therapy from Novo Nordisk is already available in Indonesia as a medical solution for patients,” she explained.
Although the GLP-1 pill is expected to reach the US market in early January 2026, the development signals where obesity treatment is heading globally.
Novo Nordisk’s GLP‑1 treatment for weight management is a prescription medicine prescribed by healthcare professionals following consultation.